• Angelini Ventures portfolio company Freya Biosciences was named to Fierce Biotech’s Fierce 15 list for 2026.
• Recognition followed positive Phase 1 results for lead candidate FB301 targeting IVF-related embryo implantation failure.
• The first-in-human study met all primary endpoints, meeting secondary endpoints.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Angelini Ventures SpA published the original content used to generate this news brief on October 05, 2026, and is solely responsible for the information contained therein.